Loading...
Parathyroid hormone (PTH) stimulates bone formation, improves trabecular architecture, and reduces fracture risk in women with postmenopausal osteoporosis. However, increases in bone resorption limit improvements in bone mineral density (BMD). Abaloparatide, a synthetic analog of human PTH-related protein, interacts differently with the PTH receptor than does teriparatide, resulting in less stimulation of bone resorption and a greater anabolic effect. In earlier studies, abaloparatide increased BMD more (and faster) than did teriparatide, suggesting that abaloparatide might be an effective therapy for osteoporosis. In a phase III study, researchers randomized 2463 postmenopausal women with osteoporosis to daily subcutaneous injections of 80…